NZ714320A - Novel antibody frameworks - Google Patents
Novel antibody frameworksInfo
- Publication number
- NZ714320A NZ714320A NZ714320A NZ71432014A NZ714320A NZ 714320 A NZ714320 A NZ 714320A NZ 714320 A NZ714320 A NZ 714320A NZ 71432014 A NZ71432014 A NZ 71432014A NZ 714320 A NZ714320 A NZ 714320A
- Authority
- NZ
- New Zealand
- Prior art keywords
- nucleic acids
- framework
- antibodies
- antibody
- iii
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13003264 | 2013-06-26 | ||
| PCT/EP2014/001730 WO2014206561A1 (en) | 2013-06-26 | 2014-06-26 | Novel antibody frameworks |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ714320A true NZ714320A (en) | 2022-02-25 |
Family
ID=48699516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ714320A NZ714320A (en) | 2013-06-26 | 2014-06-26 | Novel antibody frameworks |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10174102B2 (show.php) |
| EP (1) | EP3013864A1 (show.php) |
| JP (4) | JP6708544B2 (show.php) |
| KR (4) | KR20220029763A (show.php) |
| CN (2) | CN105579472B (show.php) |
| AU (2) | AU2014301629B2 (show.php) |
| CA (1) | CA2914829A1 (show.php) |
| HK (1) | HK1218549A1 (show.php) |
| IL (3) | IL243311B (show.php) |
| NZ (1) | NZ714320A (show.php) |
| SG (2) | SG10201811017QA (show.php) |
| WO (1) | WO2014206561A1 (show.php) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201811017QA (en) | 2013-06-26 | 2019-01-30 | Numab Innovation Ag | Novel antibody frameworks |
| CN107922486B (zh) | 2015-06-15 | 2022-05-31 | 努玛治疗有限公司 | 异源二聚体多特异性抗体形式 |
| WO2017144681A1 (en) | 2016-02-25 | 2017-08-31 | Cell Medica Switzerland Ag | Binding members to pd-l1 |
| LT3219726T (lt) | 2016-03-17 | 2021-01-25 | Tillotts Pharma Ag | Anti-tnf alfa antikūnai ir jų funkciniai fragmentai |
| EP3430042B1 (en) | 2016-03-17 | 2023-05-24 | Numab Innovation AG | Anti-tnfalpha-antibodies and functional fragments thereof |
| WO2017158079A1 (en) | 2016-03-17 | 2017-09-21 | Numab Innovation Ag | Anti-tnfalpha-antibodies and functional fragments thereof |
| LT3219727T (lt) | 2016-03-17 | 2021-02-10 | Tillotts Pharma Ag | Anti-tnf alfa antikūnai ir jų funkciniai fragmentai |
| JP6978427B2 (ja) | 2016-03-17 | 2021-12-08 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 抗ＴＮＦα抗体とその機能性フラグメント |
| GB201621591D0 (en) * | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Antibody molecules and method |
| WO2018224439A1 (en) | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-hsa antibodies |
| WO2018224441A1 (en) | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| US12098203B2 (en) | 2017-06-05 | 2024-09-24 | Numab Therapeutics AG | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA |
| EP3634998B8 (en) | 2017-06-05 | 2025-04-09 | Numab Therapeutics AG | Anti-cd3 epsilon antibodies |
| KR102754842B1 (ko) * | 2017-06-05 | 2025-01-17 | 누맙 세러퓨틱스 아게 | 신규 항 hsa 항체 |
| KR20250024104A (ko) | 2017-06-25 | 2025-02-18 | 시스트이뮨, 인코포레이티드 | 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도 |
| JP7474193B2 (ja) * | 2017-06-25 | 2024-04-24 | システィミューン， インク． | 多重特異性抗体とその作製及び使用方法 |
| EP3459968A1 (en) | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
| CA3127935A1 (en) | 2019-01-31 | 2020-08-06 | Numab Therapeutics AG | Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof |
| EP3689907A1 (en) | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
| EP4271413A4 (en) * | 2020-12-30 | 2025-07-30 | Ascendo Biotechnology Inc | MONOCLONAL ANTIBODY AGAINST HUMAN MAC-1 AND ITS USES |
| US20220259296A1 (en) | 2021-02-12 | 2022-08-18 | Boehringer Ingelheim International Gmbh | Complement c3 antigen binding proteins |
| JP2024509971A (ja) | 2021-03-11 | 2024-03-05 | アイジェニックス， インコーポレイテッド | アレルギー応答を予測するための方法およびシステム |
| IL313655A (en) | 2021-12-22 | 2024-08-01 | Boehringer Ingelheim Int | Anti-C3 antibodies and their antigen-binding fragments and their uses for the treatment of eyes or eye diseases |
| EP4611774A2 (en) * | 2022-11-04 | 2025-09-10 | MiNK Therapeutics, Inc. | B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| AU2003259718A1 (en) | 2003-08-07 | 2005-03-07 | Epitomics, Inc. | Methods for humanizing rabbit monoclonal antibodies |
| WO2008004834A1 (en) | 2006-07-06 | 2008-01-10 | Isu Abxis Co., Ltd | Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor |
| FR2910896B1 (fr) * | 2006-12-29 | 2012-11-16 | Lab Francais Du Fractionnement | Anticorps monoclonal dirige contre le recepteur humain des ldl |
| CA2688829A1 (en) | 2007-05-21 | 2008-11-27 | Alder Biopharmaceuticals, Inc. | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| EP2158315B1 (en) | 2007-06-25 | 2016-03-23 | ESBATech, an Alcon Biomedical Research Unit LLC | Methods of modifying antibodies, and modified antibodies with improved functional properties |
| EP2307458B1 (en) * | 2008-06-25 | 2018-04-11 | ESBATech, an Alcon Biomedical Research Unit LLC | Humanization of rabbit antibodies using a universal antibody framework |
| ES2793008T3 (es) * | 2008-06-25 | 2020-11-12 | Novartis Ag | Anticuerpos estables y solubles que inhiben VEGF |
| HUE053548T2 (hu) | 2008-06-25 | 2021-07-28 | Novartis Ag | Stabil és szolúbilis, TNF-gátló ellenanyagok |
| WO2010144780A1 (en) | 2009-06-12 | 2010-12-16 | University Of Kansas | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state |
| SG185107A1 (en) * | 2010-04-30 | 2012-12-28 | Alexion Pharma Inc | Antibodies having reduced immunogenicity in a human |
| WO2012163519A1 (en) * | 2011-05-27 | 2012-12-06 | Dutalys | Antibodies with improved folding stability |
| SG10201811017QA (en) | 2013-06-26 | 2019-01-30 | Numab Innovation Ag | Novel antibody frameworks |
| EP3459968A1 (en) * | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
-
2014
- 2014-06-26 SG SG10201811017QA patent/SG10201811017QA/en unknown
- 2014-06-26 EP EP14737144.7A patent/EP3013864A1/en active Pending
- 2014-06-26 CN CN201480036689.1A patent/CN105579472B/zh active Active
- 2014-06-26 AU AU2014301629A patent/AU2014301629B2/en active Active
- 2014-06-26 NZ NZ714320A patent/NZ714320A/en unknown
- 2014-06-26 CN CN202111136784.7A patent/CN113943366B/zh active Active
- 2014-06-26 CA CA2914829A patent/CA2914829A1/en active Pending
- 2014-06-26 KR KR1020227006072A patent/KR20220029763A/ko not_active Ceased
- 2014-06-26 KR KR1020237043185A patent/KR20240000622A/ko active Pending
- 2014-06-26 IL IL243311A patent/IL243311B/en unknown
- 2014-06-26 JP JP2016522319A patent/JP6708544B2/ja active Active
- 2014-06-26 KR KR1020217024096A patent/KR20210097829A/ko not_active Ceased
- 2014-06-26 WO PCT/EP2014/001730 patent/WO2014206561A1/en not_active Ceased
- 2014-06-26 KR KR1020167001339A patent/KR102286053B1/ko active Active
- 2014-06-26 IL IL293477A patent/IL293477B2/en unknown
- 2014-06-26 HK HK16106054.2A patent/HK1218549A1/zh unknown
- 2014-06-26 US US14/900,550 patent/US10174102B2/en active Active
- 2014-06-26 SG SG11201509899PA patent/SG11201509899PA/en unknown
-
2018
- 2018-10-10 US US16/156,036 patent/US11427628B2/en active Active
-
2019
- 2019-06-17 JP JP2019111990A patent/JP2019201643A/ja not_active Withdrawn
-
2020
- 2020-04-27 AU AU2020202770A patent/AU2020202770B2/en active Active
-
2021
- 2021-10-14 JP JP2021169020A patent/JP2022028659A/ja active Pending
-
2022
- 2022-08-29 US US17/822,959 patent/US20230212265A1/en active Pending
-
2023
- 2023-11-27 JP JP2023199881A patent/JP2024026176A/ja active Pending
-
2024
- 2024-06-05 IL IL313351A patent/IL313351B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ714320A (en) | Novel antibody frameworks | |
| MX2022007774A (es) | Anticuerpos de union a abril modificados. | |
| MX2014009909A (es) | Acido nucleico que comprende o codifica un tallo-bucle de histona y una secuencia poli(a) o una señal de poliadenilacion para incrementar la expresion de un antigeno tumoral codificado. | |
| MX351502B (es) | Anticuerpos de union de albumina y fragmentos de union de los mismos. | |
| WO2016168755A8 (en) | Method for mass humanization of non-human antibodies | |
| PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
| PH12014501726B1 (en) | Glyphosate resistant plants and associated methods | |
| PH12014502527B1 (en) | St2 antigen binding proteins | |
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| PH12017500892A1 (en) | Antigen binding molecules comprising a tnf family ligand trimer | |
| NZ711451A (en) | Anti-c5 antibodies having improved pharmacokinetics | |
| PH12013500315A1 (en) | Antibodies that bind myostatin, compositions and methods | |
| JO3615B1 (ar) | جسم مضاد كعامل نوعي تجاه الدايمر ألفا -4- بيتا-7-غير المتجانس | |
| CY1123405T1 (el) | Κυτταρα θηλαστικου που εκφραζουν αντιγονα κυτταρομεγαλοϊου | |
| MD4548B1 (ro) | Polipeptide care se leagă de CX3CR1 | |
| NZ717399A (en) | Antibodies against csf-1r | |
| SG10201909180SA (en) | Humanized anti-c1s antibodies and methods of use thereof | |
| NZ702839A (en) | Vaccine and methods to reduce campylobacter infection | |
| IN2015DN03206A (show.php) | ||
| HRP20220064T1 (hr) | Zglobno modificirani fragmenti protutijela i postupci za pripravu | |
| MX2016006586A (es) | Identificacion de una citocina de linfocitos b novedosa. | |
| WO2012106669A3 (en) | Foxc1 antibodies and methods of their use | |
| TN2017000441A1 (en) | Igf-1r antibody and its use for the diagnosis of cancer | |
| GB2526222A (en) | Viral peptides | |
| WO2016040767A3 (en) | Chrdl-1 epitopes and antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: NUMAB THERAPEUTICS AG, CH Effective date: 20190815 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUN 2023 BY PAVIS PAYMENT GMBH Effective date: 20220615 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUN 2024 BY PAVIS PAYMENTS GMBH Effective date: 20230612 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUN 2025 BY PAVIS PAYMENTS GMBH Effective date: 20240607 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUN 2026 BY PAVIS PAYMENT GMBH Effective date: 20250618 |